| Year |
Citation |
Score |
| 2023 |
Candelaria PV, Nava M, Daniels-Wells TR, Penichet ML. A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma. Cancers. 15. PMID 37760502 DOI: 10.3390/cancers15184533 |
0.38 |
|
| 2023 |
Daniels-Wells TR, Candelaria PV, Kranz E, Wen J, Wang L, Kamata M, Almagro JC, Martínez-Maza O, Penichet ML. Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma. Cancers. 15. PMID 36980702 DOI: 10.3390/cancers15061816 |
0.384 |
|
| 2022 |
Candelaria PV, Nava M, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997). 45: 227-230. PMID 35467582 DOI: 10.1097/CJI.0000000000000419 |
0.33 |
|
| 2022 |
Hickerson BT, Daniels-Wells TR, Payes C, Clark LE, Candelaria PV, Bailey KW, Sefing EJ, Zink S, Ziegenbein J, Abraham J, Helguera G, Penichet ML, Gowen BB. Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nature Communications. 13: 558. PMID 35091550 DOI: 10.1038/s41467-021-27949-3 |
0.318 |
|
| 2021 |
Markov SD, Caffrey TC, O' Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, ... ... Penichet ML, et al. IgE-based therapeutic combination enhances anti-tumor response in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics. PMID 34625505 DOI: 10.1158/1535-7163.MCT-21-0368 |
0.385 |
|
| 2021 |
Epeldegui M, Martínez LE, Daniels-Wells TR, Guo Y, Magpantay LI, Candelaria PV, Penichet ML, Martínez-Maza O. Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV+ human primary B-cells. Molecular Cancer Therapeutics. PMID 34158342 DOI: 10.1158/1535-7163.MCT-21-0074 |
0.389 |
|
| 2021 |
Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents. Frontiers in Immunology. 12: 607692. PMID 33815364 DOI: 10.3389/fimmu.2021.607692 |
0.435 |
|
| 2020 |
Daniels-Wells TR, Candelaria PV, Kranz E, Wen J, Weng L, Kamata M, Almagro JC, Martinez-Maza O, Penichet ML. Abstract 5655: Efficacy of antibodies targeting TfR1 in xenograft mouse models of AIDS-related non-Hodgkin lymphoma Immunology. DOI: 10.1158/1538-7445.Am2020-5655 |
0.398 |
|
| 2020 |
Candelaria PV, Nava M, Martinez-Maza O, Daniels-Wells TR, Penichet ML. Abstract 4436: Combination therapy with an antibody specific for transferrin receptor 1 (ch128.1/IgG1) and bortezomib or lenalidomide results in increased survival in an in vivo model of human multiple myeloma Immunology. 80: 4436-4436. DOI: 10.1158/1538-7445.Am2020-4436 |
0.483 |
|
| 2019 |
Daniels-Wells TR, Candelaria PV, Leoh LS, Nava M, Martínez-Maza O, Penichet ML. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 31693515 DOI: 10.1097/Cji.0000000000000304 |
0.52 |
|
| 2019 |
Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nature Communications. 10: 3850. PMID 31462642 DOI: 10.1038/S41467-019-11719-3 |
0.392 |
|
| 2019 |
Epeldegui M, Conti DV, Guo Y, Cozen W, Penichet ML, Martínez-Maza O. Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. Scientific Reports. 9: 9371. PMID 31253857 DOI: 10.1038/S41598-019-45479-3 |
0.317 |
|
| 2019 |
Luria-Pérez R, Candelaria PV, Daniels-Wells TR, Rodríguez JA, Helguera G, Penichet ML. Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein. Cytokine. 120: 220-226. PMID 31121497 DOI: 10.1016/J.Cyto.2019.04.004 |
0.364 |
|
| 2019 |
Plotkin JD, Elias MG, Fereydouni M, Daniels-Wells TR, Dellinger AL, Penichet ML, Kepley CL. Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells. Frontiers in Immunology. 10: 138. PMID 30833944 DOI: 10.3389/Fimmu.2019.00138 |
0.471 |
|
| 2019 |
Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, ... ... Penichet ML, et al. Blockade of a laminin-411 - Notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment crosstalk. Cancer Research. PMID 30659021 DOI: 10.1158/0008-5472.Can-18-2725 |
0.394 |
|
| 2019 |
Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, Hartmann K, Josephs DH, Levi-Schaffer F, Penichet ML, O'Mahony L, Poli A, Redegeld F, Roth-Walter F, Turner MC, et al. AllergoOncology: microbiota in allergy and cancer - an EAACI position paper. Allergy. PMID 30636005 DOI: 10.1111/All.13718 |
0.326 |
|
| 2019 |
Bekaii-Saab T, Overholser J, Yang Y, Penichet M, Kaumaya P. Abstract 1453: Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line Cancer Research. 79: 1453-1453. DOI: 10.1158/1538-7445.Am2019-1453 |
0.407 |
|
| 2019 |
Kaumaya PTP, Overholser J, Guo L, Yang Y, Penichet M, Sayanjali B, Ede N, Chong L, Bekaii-Saab T. Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.044 |
0.427 |
|
| 2018 |
Leoh LS, Kim YK, Candelaria PV, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. Journal of Immunology (Baltimore, Md. : 1950). PMID 29654211 DOI: 10.4049/Jimmunol.1700787 |
0.448 |
|
| 2018 |
Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, et al. Virus-like particle display of HER2 induces potent anti-cancer responses. Oncoimmunology. 7: e1408749. PMID 29399414 DOI: 10.1080/2162402X.2017.1408749 |
0.404 |
|
| 2018 |
Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy Frontiers in Immunology. 8: 1751. PMID 29379493 DOI: 10.3389/Fimmu.2017.01751 |
0.452 |
|
| 2018 |
Daniels-Wells TR, Candelaria PV, Leoh LS, Martinez-Maza O, Penichet ML. Abstract 5760: An IgG1 version of the anti-TfR1 antibody ch128.1 shows significant antitumor activity against different xenograft models of multiple myeloma Cancer Research. 78: 5760-5760. DOI: 10.1158/1538-7445.Am2018-5760 |
0.542 |
|
| 2018 |
Plotkin JD, Elias MG, Daniels-Wells TR, Dellinger A, Penichet ML, Kepley CL. Abstract 2547: A potential new autologous mast cell cancer immunotherapy Immunology. DOI: 10.1158/1538-7445.Am2018-2547 |
0.353 |
|
| 2017 |
Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D, Fiebiger E, Gould HJ, Irshad S, Janda J, Josephs DH, Levi-Schaffer F, O Mahony L, Pellizzari G, Penichet ML, et al. AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer. Allergy. PMID 28921585 DOI: 10.1111/All.13311 |
0.361 |
|
| 2017 |
Leoh LS, Kim YK, Candelaria PV, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Abstract 73: Role of macrophages in the antitumor activity of an anti-transferrin receptor 1 antibody ch128.1 in a xenograft model of multiple myeloma Cancer Research. 77: 73-73. DOI: 10.1158/1538-7445.Am2017-73 |
0.521 |
|
| 2017 |
Ljubimova J, Ding H, Galstyan A, Chiechi A, Tao S, Shatalova E, Penichet M, Ljubimov A, Holler E, Black K. SCDT-39. NANOBIOCONJUGATES CROSSING BBB FOR DELIVERY OF CHECKPOINT INHIBITORS AND ACTIVATION OF LOCAL BRAIN TUMOR IMMUNE SYSTEMS FOR GLIOMA TREATMENT Neuro-Oncology. 19: vi272-vi273. DOI: 10.1093/Neuonc/Nox168.1120 |
0.311 |
|
| 2016 |
Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, ... ... Penichet ML, et al. AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper. Allergy. PMID 28032353 DOI: 10.1111/All.13119 |
0.424 |
|
| 2016 |
Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Corrigendum to "Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1" [Mol. Immunol. 67 (2015) 407-415]. Molecular Immunology. PMID 27838011 DOI: 10.1016/J.Molimm.2016.10.005 |
0.424 |
|
| 2016 |
Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera JF, Lichtenstein A. CYTOTOXIC PROPERTIES OF A DEPTOR-mTOR INHIBITOR IN MULTIPLE MYELOMA CELLS. Cancer Research. PMID 27530328 DOI: 10.1158/0008-5472.Can-16-1019 |
0.395 |
|
| 2016 |
Daniels-Wells TR, Penichet ML. Transferrin receptor 1: a target for antibody-mediated cancer therapy. Immunotherapy. PMID 27373880 DOI: 10.2217/Imt-2016-0050 |
0.435 |
|
| 2016 |
Koru-Sengul T, Santander AM, Miao F, Sanchez LG, Jorda M, Glück S, Ince TA, Nadji M, Chen Z, Penichet ML, Cleary MP, Torroella-Kouri M. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Research and Treatment. PMID 27283835 DOI: 10.1007/S10549-016-3847-3 |
0.344 |
|
| 2016 |
Leoh LS, Kim YK, Martinez-Maza O, Daniels-Wells TR, Penichet ML. Abstract 582: Novel insights into the antitumor activity of an antibody specific for transferrin receptor 1 (ch128.1) in anin vivomodel of human multiple myeloma Cancer Research. 76: 582-582. DOI: 10.1158/1538-7445.Am2016-582 |
0.499 |
|
| 2015 |
Daniels-Wells TR, Widney DP, Leoh LS, Martínez-Maza O, Penichet ML. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 307-10. PMID 26325374 DOI: 10.1097/Cji.0000000000000092 |
0.431 |
|
| 2015 |
Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Molecular Immunology. 67: 407-15. PMID 26232328 DOI: 10.1016/J.Molimm.2015.07.001 |
0.496 |
|
| 2015 |
Leoh LS, Daniels-Wells TR, Penichet ML. IgE immunotherapy against cancer. Current Topics in Microbiology and Immunology. 388: 109-49. PMID 25553797 DOI: 10.1007/978-3-319-13725-4_6 |
0.483 |
|
| 2015 |
Leoh LS, Daniels-Wells TR, Martinez-Maza O, Penichet ML. Abstract 1335: Dissecting the mechanisms of anti-tumor protection mediated by an antibody targeting the transferrin receptor 1 Cancer Research. 75: 1335-1335. DOI: 10.1158/1538-7445.Am2015-1335 |
0.517 |
|
| 2015 |
Payés CJ, Daniels‐Wells TR, Maffía PC, Penichet ML, Morrison SL, Helguera G. Genetic Engineering of Antibody Molecules Reviews in Cell Biology and Molecular Medicine. 1: 1-52. DOI: 10.1002/3527600906.Mcb.200200007.Pub2 |
0.485 |
|
| 2014 |
De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Research : Bcr. 16: R10. PMID 24451168 DOI: 10.1186/Bcr3602 |
0.361 |
|
| 2014 |
Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Molecular Cancer Therapeutics. 13: 902-15. PMID 24448822 DOI: 10.1158/1535-7163.Mct-13-0199 |
0.497 |
|
| 2014 |
Leoh LS, Morizono K, Kershaw KM, Chen IS, Penichet ML, Daniels-Wells TR. Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. The Journal of Gene Medicine. 16: 11-27. PMID 24436117 DOI: 10.1002/Jgm.2754 |
0.473 |
|
| 2013 |
Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet ML, Martinez-Maza O. Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. Plos One. 8: e72414. PMID 23936541 DOI: 10.1371/Journal.Pone.0072414 |
0.417 |
|
| 2013 |
Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 171: 322-9. PMID 23770212 DOI: 10.1016/J.Jconrel.2013.06.001 |
0.504 |
|
| 2013 |
Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. Bmc Cancer. 13: 195. PMID 23594731 DOI: 10.1186/1471-2407-13-195 |
0.396 |
|
| 2013 |
Daniels-Wells TR, Helguera G, RodrÃguez JA, Leoh LS, Erb MA, Diamante G, Casero D, Pellegrini M, MartÃnez-Maza O, Penichet ML. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicology in Vitro : An International Journal Published in Association With Bibra. 27: 220-31. PMID 23085102 DOI: 10.1016/J.Tiv.2012.10.006 |
0.425 |
|
| 2013 |
Leoh LS, Erb MA, Morizono K, Chen ISY, Penichet ML, Daniels-Wells TR. Abstract 3321: Novel therapeutic approaches targeting the transferrin receptor 1 for the treatment of mantle cell lymphoma. Cancer Research. 73: 3321-3321. DOI: 10.1158/1538-7445.Am2013-3321 |
0.521 |
|
| 2013 |
Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Abstract 2848: IgE-mediated immune activation targeting the prostate specific antigen: a potential prostate cancer therapy. Cancer Research. 73: 2848-2848. DOI: 10.1158/1538-7445.Am2013-2848 |
0.478 |
|
| 2013 |
Daniels-Wells TR, Leoh LS, Widney D, Thapa DR, Merino JL, Magpantay L, Martínez-Maza O, Penichet ML. Abstract 1240: A flexible antibody-based strategy targeting CD71 for the treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Research. 73: 1240-1240. DOI: 10.1158/1538-7445.Am2013-1240 |
0.47 |
|
| 2012 |
Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Research and Treatment. 136: 647-58. PMID 23065001 DOI: 10.1007/S10549-012-2264-5 |
0.373 |
|
| 2012 |
Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clinical Lymphoma, Myeloma & Leukemia. 12: 155-63. PMID 22440007 DOI: 10.1016/J.Clml.2012.01.006 |
0.351 |
|
| 2012 |
Helguera G, Jemielity S, Abraham J, Cordo SM, Martinez MG, RodrÃguez JA, Bregni C, Wang JJ, Farzan M, Penichet ML, Candurra NA, Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses. Journal of Virology. 86: 4024-8. PMID 22278244 DOI: 10.1128/Jvi.06397-11 |
0.419 |
|
| 2012 |
Daniels TR, MartÃnez-Maza O, Penichet ML. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 61: 1535-46. PMID 22193986 DOI: 10.1007/S00262-011-1169-1 |
0.538 |
|
| 2012 |
Daniels TR, Leuchter RK, Quintero R, Helguera G, RodrÃguez JA, MartÃnez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunology, Immunotherapy : Cii. 61: 991-1003. PMID 22127364 DOI: 10.1007/S00262-011-1150-Z |
0.533 |
|
| 2012 |
Daniels TR, Bernabeu E, RodrÃguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica Et Biophysica Acta. 1820: 291-317. PMID 21851850 DOI: 10.1016/J.Bbagen.2011.07.016 |
0.39 |
|
| 2011 |
Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum On Immunopathological Diseases and Therapeutics. 2. PMID 24286018 DOI: 10.1615/Forumimmundisther.V2.I2.90 |
0.36 |
|
| 2011 |
Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. Bmc Cancer. 11: 471. PMID 22044845 DOI: 10.1186/1471-2407-11-471 |
0.366 |
|
| 2011 |
RodrÃguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, MartÃnez-Maza O, Charles AC, Pellegrini M, Helguera G, ... Penichet ML, et al. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia & Lymphoma. 52: 2169-78. PMID 21870996 DOI: 10.3109/10428194.2011.596964 |
0.471 |
|
| 2011 |
Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, MartÃnez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 500-8. PMID 21654517 DOI: 10.1097/Cji.0B013E318222Ffc8 |
0.474 |
|
| 2011 |
Helguera G, Rodríguez JA, Luria-Pérez R, Henery S, Catterton P, Bregni C, George TC, Martínez-Maza O, Penichet ML. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. Journal of Immunological Methods. 368: 54-63. PMID 21420412 DOI: 10.1016/J.Jim.2011.03.003 |
0.443 |
|
| 2011 |
Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M, Gates M, Patil R, Penichet ML, Ljubimov AV, Black KL, Holler E, et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Research. 71: 1454-64. PMID 21303974 DOI: 10.1158/0008-5472.Can-10-3093 |
0.462 |
|
| 2011 |
Bermudez-Fajardo A, Stark AK, El-Kadri R, Penichet ML, Hölzle K, Wittenbrink MM, Hölzle L, Oviedo-Orta E. The effect of Chlamydophila pneumoniae Major Outer Membrane Protein (MOMP) on macrophage and T cell-mediated immune responses Immunobiology. 216: 152-163. PMID 20637522 DOI: 10.1016/J.Imbio.2010.06.004 |
0.344 |
|
| 2011 |
Liu H, Huerta-Yepez S, Rivera-Pazos CM, Cabera-Muñoz MdL, Baritaki S, Vardanyan S, Penichet ML, Chen H, Berenson JR, Bonavida B. Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan, Blood. 118: 3991-3991. DOI: 10.1182/Blood.V118.21.3991.3991 |
0.386 |
|
| 2011 |
Huerta-Yepez S, Baritaki S, Liu H, Mendez-Maldonado KM, Penichet ML, Vega MI, Martinez-Maza O, Chen H, Berenson JR, Chatterjee D, Bonavida B. The Overexpression of Inactive Phosphorylated Raf-1 Kinase Inhibitory Protein (RKIP) in Multiple Myeloma (MM) Regulates the Resistance to Bortezomib-Induced Cytotoxicity: Reversal of Resistance by the PKC Inhibitor Bisindolylmalemide Blood. 118: 2892-2892. DOI: 10.1182/Blood.V118.21.2892.2892 |
0.403 |
|
| 2011 |
Daniels TR, Ortiz-Sanchez E, Luria-Perez R, Quintero R, Helguera G, Bonavida B, Martinez-Maza O, Penichet ML. Abstract 3622: An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of multiple myeloma Cancer Research. 71: 3622-3622. DOI: 10.1158/1538-7445.Am2011-3622 |
0.495 |
|
| 2010 |
Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet ML, Montano RF. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg Molecular Cancer Therapeutics. 9: 2175-2185. PMID 20682652 DOI: 10.1158/1535-7163.Mct-09-1054 |
0.496 |
|
| 2010 |
Daniels TR, Neacato II, RodrÃguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 24: 1555-65. PMID 20574452 DOI: 10.1038/Leu.2010.142 |
0.464 |
|
| 2010 |
Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. International Journal of Oncology. 36: 1299-307. PMID 20372806 DOI: 10.3892/Ijo_00000615 |
0.43 |
|
| 2010 |
Luria-Perez R, Helguera GF, Quintero R, Cruz ALD, Rodriguez JA, Daniels TR, Penichet ML. Abstract LB-304: Novel antibody-(IL-12) fusion proteins with disrupted heparin-binding activity for the therapy of cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-304 |
0.479 |
|
| 2010 |
Rodríguez JA, López-Valdes HE, Helguera GF, So S, Luria-Pérez R, Daniels TR, Charles AC, Penichet ML. Abstract 4456: Molecular events required for the induction of lethal iron deprivation in malignant hematopoietic cells via an antibody-avidin fusion protein specific for human transferrin receptor 1 Cancer Research. 70: 4456-4456. DOI: 10.1158/1538-7445.Am10-4456 |
0.422 |
|
| 2010 |
Inoue S, Ding H, Konda B, Portilla-Arias J, Patil R, Espinoza A, Rudenkyy S, Penichet ML, Riley M, Gates M, Holler E, Black KL, Ljubimova JY. Abstract 3854: Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer Cancer Research. 70: 3854-3854. DOI: 10.1158/1538-7445.Am10-3854 |
0.489 |
|
| 2010 |
Daniels TR, Rodríguez JA, Ortiz-Sánchez E, Helguera G, Penichet ML. The IgE antibody and its use in cancer immunotherapy Cancer and Ige: Introducing the Concept of Allergooncology. 159-183. DOI: 10.1007/978-1-60761-451-7_7 |
0.451 |
|
| 2010 |
Penichet ML, Jensen-Jarolim E. Cancer and IgE: Introducing the concept of allergooncology Cancer and Ige: Introducing the Concept of Allergooncology. 1-287. DOI: 10.1007/978-1-60761-451-7 |
0.392 |
|
| 2009 |
Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Research : Bcr. 11: R36. PMID 19531256 DOI: 10.1186/Bcr2321 |
0.326 |
|
| 2009 |
Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet ML, Chen IS. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. The Journal of Gene Medicine. 11: 655-63. PMID 19455593 DOI: 10.1002/Jgm.1345 |
0.409 |
|
| 2009 |
Ortiz-Sánchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 23: 59-70. PMID 18946492 DOI: 10.1038/leu.2008.270 |
0.36 |
|
| 2009 |
Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy : Cii. 58: 915-30. PMID 18941743 DOI: 10.1007/S00262-008-0607-1 |
0.422 |
|
| 2009 |
Montano RF, Penichet ML, Blackall DP, Morrison SL, Chintalacharuvu KR. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents. Journal of Immunological Methods. 340: 1-10. PMID 18848836 DOI: 10.1016/J.Jim.2008.09.011 |
0.45 |
|
| 2008 |
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H. AllergoOncology: The role of IgE-mediated allergy in cancer Allergy: European Journal of Allergy and Clinical Immunology. 63: 1255-1266. PMID 18671772 DOI: 10.1111/J.1398-9995.2008.01768.X |
0.477 |
|
| 2008 |
Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis Clinical and Developmental Immunology. 2008. PMID 18551190 DOI: 10.1155/2008/723539 |
0.315 |
|
| 2008 |
Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 6199-210. PMID 18424742 DOI: 10.4049/Jimmunol.180.9.6199 |
0.363 |
|
| 2008 |
Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opinion On Biological Therapy. 8: 609-32. PMID 18407765 DOI: 10.1517/14712598.8.5.609 |
0.492 |
|
| 2008 |
Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Molecular Cancer Therapeutics. 7: 721-9. PMID 18347157 DOI: 10.1158/1535-7163.Mct-07-2067 |
0.474 |
|
| 2008 |
Suzuki E, Umezawa K, Helguera G, Daniels TR, Schiller G, Berenson JR, Penichet ML, Bonavida B. Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis Blood. 112: 4473-4473. DOI: 10.1182/Blood.V112.11.4473.4473 |
0.433 |
|
| 2008 |
Baritaki S, Rodriguez J, Helguera G, Martinez-Paniagua M, Vega M, Huerta-Yepez S, Jazirehi A, Spandidos D, Penichet ML, Bonavida B. Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance Blood. 112: 3770-3770. DOI: 10.1182/Blood.V112.11.3770.3770 |
0.329 |
|
| 2008 |
Baritaki S, Huerta-Yepez S, de Lourdes Cabera-Muñoz M, Rivera-Pazos C, Yeung K, Penichet ML, Chen H, Berenson JR, Bonavida B. Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM): RKIP Overexpression and RKIP Phosphorylation Is Common in MM Tumor Cells Blood. 112: 2729-2729. DOI: 10.1182/Blood.V112.11.2729.2729 |
0.405 |
|
| 2008 |
Rodriguez JA, Helguera G, Daniels TR, Diaz-Cano DC, Ortiz-Sanchez E, Coppola G, Pellegrini M, Martinez-Maza O, Penichet ML. Cellular and Molecular Mechanisms of Sensitivity and Resistance of Hematopoietic Malignant Cells to Treatment with ch128.1Av, An Antibody-Avidin Fusion Protein Specific for Human Transferrin Receptor 1 (CD71). Blood. 112: 1608-1608. DOI: 10.1182/Blood.V112.11.1608.1608 |
0.444 |
|
| 2008 |
Singer J, Karagiannis P, Karagiannis S, Gan S, Hunt J, Knittelfelder R, Beavil A, Penichet M, Jensen-Jarolim E, Gould H. Su.67. Establishing a Model for Examination of HER-2 Specific IgG and IgE Mediated Tumour Cell Killing Clinical Immunology. 127. DOI: 10.1016/J.Clim.2008.03.418 |
0.398 |
|
| 2007 |
Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Molecular Cancer Therapeutics. 6: 2995-3008. PMID 18025284 DOI: 10.1158/1535-7163.Mct-07-0330 |
0.518 |
|
| 2007 |
RodrÃguez JA, Helguera G, Daniels TR, Neacato II, López-Valdés HE, Charles AC, Penichet ML. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. Journal of Controlled Release : Official Journal of the Controlled Release Society. 124: 35-42. PMID 17884229 DOI: 10.1016/J.Jconrel.2007.08.020 |
0.503 |
|
| 2007 |
Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, Ding H, Holler E, Black KL, Ljubimova JY. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). Journal of Controlled Release : Official Journal of the Controlled Release Society. 122: 356-63. PMID 17630012 DOI: 10.1016/J.Jconrel.2007.05.032 |
0.473 |
|
| 2007 |
Helguera G, RodrÃguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunology, Immunotherapy : Cii. 56: 1507-12. PMID 17310381 DOI: 10.1007/S00262-007-0297-0 |
0.479 |
|
| 2007 |
Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood. 109: 3915-21. PMID 17213289 DOI: 10.1182/Blood-2006-07-037671 |
0.364 |
|
| 2007 |
Baritaki S, Huerta-Yepez S, Yeung K, Penichet M, Chen H, Shalitin D, Berenson J, Bonavida B. Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP Is Common in MM Tumor Cells. Blood. 110: 4852-4852. DOI: 10.1182/Blood.V110.11.4852.4852 |
0.412 |
|
| 2007 |
Ortiz-Sanchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. The Role of Iron in the Cytotoxicity Induced in Hematopoietic Malignant Cell Lines by an Anti-Transferrin Receptor IgG3-Avidin Fusion Protein and Gambogic Acid. Blood. 110: 4204-4204. DOI: 10.1182/Blood.V110.11.4204.4204 |
0.429 |
|
| 2007 |
Helguera G, Rodriguez JA, Daniels TR, Diaz-Cano DC, Pellegrini M, Penichet ML. Insights into the Genetic Signature Associated with Cell Death Induced by an Antibody-Avidin Fusion Protein Specific for Transferrin Receptor. Blood. 110: 3476-3476. DOI: 10.1182/Blood.V110.11.3476.3476 |
0.445 |
|
| 2006 |
Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology (Orlando, Fla.). 121: 159-76. PMID 16920030 DOI: 10.1016/J.Clim.2006.06.006 |
0.495 |
|
| 2006 |
Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology (Orlando, Fla.). 121: 144-58. PMID 16904380 DOI: 10.1016/J.Clim.2006.06.010 |
0.491 |
|
| 2006 |
Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 108: 2745-54. PMID 16804109 DOI: 10.1182/Blood-2006-04-020263 |
0.484 |
|
| 2006 |
Helguera G, Rodríguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors Molecular Cancer Therapeutics. 5: 1029-1040. PMID 16648575 DOI: 10.1158/1535-7163.Mct-05-0488 |
0.391 |
|
| 2006 |
Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine. 24: 304-16. PMID 16125282 DOI: 10.1016/J.Vaccine.2005.07.073 |
0.4 |
|
| 2006 |
Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Molecular Immunology. 43: 667-76. PMID 15908002 DOI: 10.1016/J.Molimm.2005.04.007 |
0.508 |
|
| 2006 |
Penichet ML, Morrison SL. Antibody Molecules, Genetic Engineering of Reviews in Cell Biology and Molecular Medicine. DOI: 10.1002/3527600906.Mcb.200200007 |
0.461 |
|
| 2005 |
Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine. 23: 4793-803. PMID 15967544 DOI: 10.1016/J.Vaccine.2005.04.041 |
0.489 |
|
| 2005 |
Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Molecular Cancer Therapeutics. 4: 956-67. PMID 15956253 DOI: 10.1158/1535-7163.Mct-04-0321 |
0.469 |
|
| 2005 |
Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomolecular Engineering. 21: 145-55. PMID 15748688 DOI: 10.1016/J.Bioeng.2004.10.001 |
0.483 |
|
| 2005 |
Helguera G, Penichet ML. Antibody-cytokine fusion proteins for the therapy of cancer Methods in Molecular Medicine. 109: 347-374. PMID 15585931 DOI: 10.1385/1-59259-862-5:347 |
0.488 |
|
| 2005 |
Suzuki E, Gan X, Umezawa K, Helguera G, Schiller G, Penichet M, Bonavida B. Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av. Blood. 106: 5119-5119. DOI: 10.1182/Blood.V106.11.5119.5119 |
0.499 |
|
| 2004 |
Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clinical and Experimental Medicine. 4: 57-64. PMID 15672942 DOI: 10.1007/S10238-004-0039-Y |
0.498 |
|
| 2004 |
Penichet ML, Morrison SL. Design and engineering human forms of monoclonal antibodies Drug Development Research. 61: 121-136. DOI: 10.1002/Ddr.10347 |
0.465 |
|
| 2003 |
Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine. 21: 1317-26. PMID 12615426 DOI: 10.1016/S0264-410X(02)00741-7 |
0.436 |
|
| 2003 |
Penichet M. Recombinant antibodies for cancer therapy: methods and protocols Clinical Immunology. 106: 238-239. DOI: 10.1016/S1521-6616(02)00053-0 |
0.4 |
|
| 2002 |
Helguera G, Morrison SL, Penichet ML. Antibody-cytokine fusion proteins: Harnessing the combined power of cytokines and antibodies for cancer therapy Clinical Immunology. 105: 233-246. PMID 12498805 DOI: 10.1006/Clim.2002.5302 |
0.492 |
|
| 2002 |
Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 10706-11. PMID 12149472 DOI: 10.1073/Pnas.162362999 |
0.47 |
|
| 2002 |
Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. Myeloma expression systems. Journal of Immunological Methods. 261: 1-20. PMID 11861062 DOI: 10.1016/S0022-1759(01)00559-2 |
0.479 |
|
| 2001 |
Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 21: 709-20. PMID 11576465 DOI: 10.1089/107999001753124444 |
0.492 |
|
| 2001 |
Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Human Antibodies. 10: 43-9. PMID 11455061 DOI: 10.3233/Hab-2000-10107 |
0.476 |
|
| 2001 |
Penichet ML, Dela Cruz JS, Challita-Eid PM, Rosenblatt JD, Morrison SL. A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Cancer Immunology, Immunotherapy : Cii. 49: 649-62. PMID 11258791 DOI: 10.1007/S002620000155 |
0.447 |
|
| 2001 |
Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. Journal of Immunological Methods. 248: 91-101. PMID 11223071 DOI: 10.1016/S0022-1759(00)00345-8 |
0.514 |
|
| 2000 |
Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 165: 5112-21. PMID 11046042 DOI: 10.4049/Jimmunol.165.9.5112 |
0.518 |
|
| 1999 |
Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice Laboratory Animal Science. 49: 179-188. PMID 10331548 |
0.414 |
|
| 1998 |
Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V, Rosenblatt JD. A RANTES-antibody fusion protein retains antigen specificity and chemokine function Journal of Immunology. 161: 3729-3736. PMID 9759898 |
0.423 |
|
| 1998 |
Penichet ML, Harvill ET, Morrison SL. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity Journal of Interferon and Cytokine Research. 18: 597-607. PMID 9726441 DOI: 10.1089/Jir.1998.18.597 |
0.412 |
|
| 1998 |
Challita-Eid PM, Penichet ML, Shin SU, Poles T, Mosammaparast N, Mahmood K, Slamon DJ, Morrison SL, Rosenblatt JD. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway Journal of Immunology. 160: 3419-3426. PMID 9531302 |
0.336 |
|
| 1997 |
Penichet ML, Harvill ET, Morrison SL. Antibody-IL-2 fusion proteins: A novel strategy for immune potentiation Human Antibodies. 8: 106-118. PMID 9322080 DOI: 10.3233/Hab-1997-8301 |
0.515 |
|
| 1997 |
Challita PM, Abboud CN, Rosell KE, Penichet M, Morrison SL, Rossenblatt JD. CHARACTERIZATION OF A RANTES-ANTIBODY FUSION PROTEIN FOR CANCER IMMUNOTHERAPY Journal of Immunotherapy. 20: 416. DOI: 10.1097/00002371-199709000-00076 |
0.437 |
|
| Show low-probability matches. |